Cited by 204Glioma Diagnosis and TreatmentCancer Cells and MetastasisNeurogenesis and neuroplasticity mechanisms

Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition

Open access
Ying, M, Wang, S, Sang, Y, Sun, P, Lal, B, Goodwin, C R, Guerrero-Cazares, H, Quinones-Hinojosa, A +2 more·2011·Oncogene

Abstract

It is necessary to understand mechanisms by which differentiating agents influence tumor-initiating cancer stem cells. Toward this end, we investigated the cellular and molecular responses of glioblastoma stem-like cells (GBM-SCs) to all-trans retinoic acid (RA). GBM-SCs were grown as non-adherent neurospheres in growth factor supplemented serum-free medium. RA treatment rapidly induced morphology changes, induced growth arrest at G1/G0 to S transition, decreased cyclin D1 expression and increased p27 expression. Immunofluorescence and western blot analysis indicated that RA induced the expression of lineage-specific differentiation markers Tuj1 and GFAP and reduced the expression of neural stem cell markers such as CD133, Msi-1, nestin and Sox-2. RA treatment dramatically decreased neurosphere-forming capacity, inhibited the ability of neurospheres to form colonies in soft agar and inhibited their capacity to propagate subcutaneous and intracranial xenografts. Expression microarray analysis identified ∼350 genes that were altered within 48 h of RA treatment. Affected pathways included retinoid signaling and metabolism, cell-cycle regulation, lineage determination, cell adhesion, cell-matrix interaction and cytoskeleton remodeling. Notch signaling was the most prominent of these RA-responsive pathways. Notch pathway downregulation was confirmed based on the downregulation of HES and HEY family members. Constitutive activation of Notch signaling with the Notch intracellular domain rescued GBM neurospheres from the RA-induced differentiation and stem cell depletion. Our findings identify mechanisms by which RA targets GBM-derived stem-like tumor-initiating cells and novel targets applicable to differentiation therapies for glioblastoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2011.58

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ying, M., Wang, S., Sang, Y., Sun, P., Lal, B., Goodwin, C. R., Guerrero-Cazares, H., Quinones-Hinojosa, A., Laterra, J., & Xia, S.
Affiliations
Kennedy Krieger Institute (US)
Corresponding author
Xia, S
Venue
Oncogene
Published
2011-03-07
Volume
30
Issue
31
Pages
3454-3467
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2105823026
Cited by
204
References
55
Citations by year
2026: 3 · 2025: 7 · 2024: 11 · 2023: 14 · 2022: 12 · 2021: 18 · 2020: 12 · 2019: 13 · 2018: 14 · 2017: 13 · 2016: 15 · 2015: 15 · 2014: 17 · 2013: 14 · 2012: 20
FWCI
9.22
Type
journal article
Language
en
Open access
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Foundation for the National Institutes of Health
  • Howard Hughes Medical Institute
  • James S. McDonnell Foundation
  • National Institute of Neurological Disorders and Stroke (R01NS043987)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Keywords
glioblastoma stem cells, all-trans retinoic acid, Notch signaling, cancer stem cell differentiation, neurospheres, cyclin D1, p27, Notch intracellular domain, cancer stem cells, retinoid signaling, cell cycle arrest
MeSH terms
AC133 Antigen, Animals, Antineoplastic Agents, Brain Neoplasms, Cell Differentiation, Female, Glial Fibrillary Acidic Protein, Glioblastoma, Glycoproteins, Humans, Intermediate Filament Proteins, Mice, Nude, Nerve Tissue Proteins, Peptides, Tretinoin, Tubulin, Neoplastic Stem Cells, Antigens, CD, Gene Expression Regulation, Neoplastic, RNA-Binding Proteins, Proliferating Cell Nuclear Antigen, Cyclin D1, Gene Expression Profiling, Cell Line, Tumor, Mice, Receptors, Notch, SOXB1 Transcription Factors, Nestin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review